Anthropic CEO Dario Amodei Says AI Could Cure Cancer Within a Decade

Anthropic CEO Dario Amodei says artificial intelligence will eliminate cancer, Alzheimer's, heart disease and mental illness in less than ten years. "You know, if today we look at things like cancer, Alzheimer's, heart disease, mental illness, these will be relics of the past in, I think, less than a decade," Amodei said. The claim, delivered with full attribution to the executive himself, is among the boldest medical forecasts issued by any major AI company leader to date.

Amodei did not stop at disease. "I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia," he added, according to the remarks reported in a Wall Street Lunch podcast segment (0:14). The statement is unqualified in scope: he named four of the leading causes of death and disability worldwide and attached a timeline of under ten years to their disappearance.

Why the timing of the claim matters

The prediction arrives as Anthropic, trading under the ticker ANT, moves toward a public listing. The Financial Times reports that Anthropic's bankers are considering raising the company's IPO price range following strong investor demand, according to the podcast's summary of the report.

Underwriters led by Goldman Sachs and Morgan Stanley may boost the range above the $70 to $78 per-share band provided in Tuesday's filing. Such a move, the report states, could potentially lift Anthropic's valuation target to $1.5 trillion or higher.

The juxtaposition is hard to ignore. A CEO predicting the end of major disease within a decade is also running a company whose advisers are weighing a valuation above $1.5 trillion. Amodei's framing of an "age of miracles" and the podcast's own framing — which noted that the "ability to eliminate every health concern on the planet dovetails nicely with Anthropic tapping the capital markets" — places the medical claims squarely in a fundraising context. The show's host added a sardonic note to that effect: "Get that up to $2T and maybe they'll throw in world peace."

What did CoreWeave's quarter do to the AI cloud sector?

The second story in the segment (1:13) concerns CoreWeave, whose "breakout quarter" and strong guidance — covered earlier on the podcast's sister program Wall Street Breakfast — are helping other neocloud stocks, the term for smaller cloud-computing providers focused on AI workloads.

Five CoreWeave competitors moved higher in the session, according to the report:

• Nebius (NBIS)
• IREN (IREN)
• Cipher Digital (CIFR)
• Applied Digital (APLD)
• Core Scientific (CORZ)

The move illustrates the extent to which CoreWeave now functions as a bellwether for the niche. One company's results and guidance lifted an entire cohort of AI infrastructure stocks in a single session.

Why is Rigetti down despite long-term optimism?

Rigetti Computing (RGTI) traded lower after its Q3 results fell shy of expectations. The quantum computing company's shortfall did not, however, shake analyst confidence in its long-term prospects.

StoneX Financial analyst Gary Mobley provided the segment's most detailed analytical quote: "gate-based quantum computers, such as those developed by RGTI, are years away from being commercial-grade and fault-tolerant, RGTI's sales, bookings and RPOs will remain lumpy on a quarterly basis."

Mobley's comment contains the key technical context: gate-based quantum computing (a design that processes information through logic gates analogous to classical circuits) remains years from commercial-grade, fault-tolerant operation. RPOs — remaining performance obligations, a measure of contracted future revenue — will, in his view, arrive unevenly quarter to quarter. That explains the divergence: a quarterly miss, a lower share price, and sustained long-term optimism from the covering analyst.

Who is buying Six Flags stock, and why?

Six Flags Entertainment (FUN) rose after insider buying from three named categories of purchaser: its executive chairman, a director, and its chief legal officer.

The purchases come against an activist backdrop. Jana Partners has joined a growing list of investors reportedly pushing for a sale of the company, according to the report. The context for that pressure is blunt: Six Flags shares are down 28% this year. Insider buying at a company facing sale demands from activists including Jana Partners gives the move a signal value that ordinary executive purchases might not carry.

What does MotorTrend's award mean for Rivian?

The final segment (2:03) covers Rivian (RIVN), whose R2 SUV has been named MotorTrend's 2027 SUV of the Year. The award arrives four years after Rivian's R1T pickup earned the publication's Truck of the Year designation.

MotorTrend's citation, quoted in full in the report, praised the R2's "clean, attractive, brand-affirming style, sensational driving dynamics, and enough luxury and utility to truly serve as a one-vehicle solution." The magazine went further, calling the R2 "something of a miracle."

That language lands at a critical moment for the company. Rivian, per the report, has been plagued by lackluster sales and crippling cash burn. The R2 represents the company's attempt to change that trajectory, and the MotorTrend designation gives the vehicle a high-profile endorsement as it enters a market that has so far punished the automaker's financials.

The connective thread

Three of the four stories in the segment turn on the same mechanism: a high-visibility declaration — a CEO's medical prophecy, a breakout quarter, an editor's award — moving money or expectations in its wake. Anthropic's Amodei made the largest claim, a decade-long horizon for the end of major disease, while his underwriters weigh a valuation of $1.5 trillion or more. The Financial Times report on a possible price-range increase above $70 to $78 gives investors a concrete number to watch as the IPO proceeds; Amodei's own words, "an age of miracles," will likely follow the filing for exactly as long as the valuation debate does.

A note on the securities discussed: the original report flags that one or more of the stocks mentioned do not trade on a major U.S. exchange, and advises readers to be aware of the associated risks.